目的 探究健脾祛濕方（JPQS）抗肥胖作用及對(duì)脂質(zhì)代謝和慢性炎癥的影響。方法 56只雄性SD大鼠適應(yīng)性飼養(yǎng)1周后，隨機(jī)分為對(duì)照組、模型組、奧利司他（32.4 mg·kg^-1）組及JPQS高、低劑量（0.70、0.35 g·kg^-1）組。對(duì)照組給予純化飼料，其余各組給予高脂飼料喂養(yǎng)，持續(xù)8周，建立單純性肥胖大鼠模型。造模同時(shí)ig給藥干預(yù)，每天1次，對(duì)照組和模型組每日ig給予蒸餾水，連續(xù)給藥8周。末次給藥后，測(cè)定大鼠體質(zhì)量、內(nèi)臟白色脂肪含量、脂體比、Lee’s指數(shù)等。采用酶聯(lián)免疫法（ELISA）檢測(cè)各組大鼠血清中脂聯(lián)素（ADP）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）的水平；采用實(shí)時(shí)熒光定量PCR（qRT-PCR）技術(shù)檢測(cè)各組大鼠附睪旁脂肪的脂肪酸合成酶（FAS）、脂肪三酰甘油水解酶（ATGL）和脂蛋白脂肪酶（LPL）的mRNA相對(duì)表達(dá)量；采用蘇木精-伊紅（HE）染色法觀(guān)察各組大鼠肝臟及附睪旁白色脂肪組織的形態(tài)；采用油紅O染色法觀(guān)察各組大鼠肝臟脂滴沉積情況。結(jié)果 與對(duì)照組比較，模型組大鼠的體質(zhì)量、體質(zhì)量增重、Lee’s指數(shù)、內(nèi)臟脂肪含量及脂體比均顯著升高（P＜0.05、0.01、0.001）； ADP含量顯著降低（P＜0.05），TNF-α和IL-6含量顯著升高（P＜0.01）； FAS mRNA水平顯著升高（P＜0.05），ATGL和LPL mRNA水平顯著降低（P＜0.05）。與模型組相比，JPQS高、低劑量組大鼠的體質(zhì)量、體質(zhì)量增重、Lee’s指數(shù)、內(nèi)臟脂肪含量及脂體比均顯著降低（P＜0.05、0.01、0.001），攝食量無(wú)明顯影響； ADP含量顯著增多（P＜0.05），TNF-α和IL-6含量顯著降低（P＜0.01、0.001）； FAS mRNA水平顯著減少（P＜0.01），ATGL和LPL mRNA水平顯著升高（P＜0.05、0.01、0.001）。結(jié)論 JPQS可以通過(guò)抑制體質(zhì)量及內(nèi)臟脂肪含量的增長(zhǎng)進(jìn)而預(yù)防肥胖的發(fā)生發(fā)展，其機(jī)制可能與改善脂質(zhì)代謝及緩解慢性炎癥有關(guān)。

Objective To explore the anti-obesity effect of Jianpi-Qushi Prescription (JPQS) on simple obese rats and its effects on lipid metabolism and chronic inflammation. Methods After one week of adaptive feeding, 56 male SD rats were randomly divided into the control group, the model group, the orlistat (32.4 mg·kg^-1) group and the high-dose (0.70 g·kg^-1) and low-dose (0.35 g·kg^-1) JPQS groups. The control group was fed with purified feed, while the other groups were fed with high-fat feed for eight weeks to establish a simple obesity rat model. At the same time of modeling, ig administration was given once a day. The control group and the model group were ig administered with distilled water daily for eight consecutive weeks. After the last administration, the weight, visceral white fat content, fat-body ratio, Lee's index and other indicators were measured. The levels of serum adiponectin (ADP), tumor necrosis factor-α (TNF-α) and interleukin -6 (IL-6) were detected by enzyme-linked immunosorbent assay (ELISA). The relative mRNA expression of fatty acid synthase (FAS), adipose triglyceride lipase (ATGL) and lipoprotein lipase (LPL) in epididymal fat of rats in each group was detected by real-time fluorescence quantitative PCR (qRT-PCR). Hematoxylin-eosin (HE) staining was used to observe the morphology of liver and white adipose tissue of rats in each group. Oil red O staining was used to observe the deposition of lipid droplet of liver. Results Compared with the control group, the body weight, weight gain, Lee's index, visceral fat content and fat-body ratio of rats in model group were significantly decreased (P <0.05, 0.01, 0.001). The level of ADP increased significantly (P < 0.05), while the level of TNF-α and IL-6 decreased significantly (P < 0.01); The relative mRNA expression of FAS was downregluated significantly (P < 0.05), while the relative mRNA expression of ATGL and LPL were up-regluated significantly (P < 0.05). Compared with the model group, the body weight, weight gain, Lee's index, visceral fat content and fat-body ratio of rats in the high and low dose groups of JPQS were significantly decreased (P < 0.05, 0.01, 0.001), but the food intake had no obvious effect. The level of ADP increased significantly (P < 0.05), while the level of TNF-α and IL-6 decreased significantly (P < 0.01); The relative mRNA expression of FAS down-regluated significantly (P < 0.01), while the relative mRNA expression of ATGL and LPL up-regluated significantly (P < 0.05, 0.01, 0.001). Conclusion JPQS could prevent obesity by inhibiting the growth of body weight and visceral fat content, and its mechanism may be related to improving lipid metabolism and relieving chronic inflammation.

R285.5

國(guó)家重點(diǎn)研發(fā)計(jì)劃項(xiàng)目（2018YFC1706804）